enGene Updates Pivotal Bladder Cancer Data and Announces Executive Appointments

enGene Therapeutics reported updated LEGEND Phase 2 results for detalimogene voraplasmid in high-risk, BCG-unresponsive non-muscle invasive bladder cancer, saying Cohort 1 showed improved efficacy. The company said recent FDA discussions established a path to begin a biologics license application submission before the end of 2026, with potential approval in 2027. Dr. Erik T. Goluboff was appointed Chief Medical Officer and Jason Duncan Chief Legal and Administrative Officer, effective November 9, 2026.